Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MorphoSys gets FDA fast track status for lymphoma drug MOR208
DLBCL accounts for about 25% of all NHLs in the developed world and it occurs primarily in older individuals, while the disease can also occur in children and
DLBCL accounts for about 25% of all NHLs in the developed world and it occurs primarily in older individuals, while the disease can also occur in children and
The pancreatic cancer treatment includes implanting living cells that have been encapsulated in pin-head sized, cellulose-based, protective cocoons through the use of the Cell-in-a-Box technology, followed by the
Conducted in 35 centres in Korea, Taiwan, Hong Kong and India, the trial is designed to assess the safety and efficacy of intravenous Brinavess in patients with recent-onset
ORSL is a fruit-based drink useful for electrolytes restoration during mild dehydration and general disability. It is generally used following cough & cold, pain, fever and other digestive
The trial showed that these patients with the most common type of EGFR mutation, (exon 19 deletion; del19), lived significantly longer after receiving first-line treatment with afatinib compared
The NDA supports the use of the regimen among adult and adolescent treatment-naïve HIV individuals, virologically suppressed patients who switch regimens and those with renal impairment. The company
University of California associate professor of Neurological Surgery and principal investigator of the study Dr Nicholas Butowski is sponsoring and conducting the Phase I trial and it is
SPK-RPE65 targets a group of blinding conditions known as inherited retinal dystrophies (IRDs). IRDs are caused by autosomal recessive mutations in the RPE65 gene, for which currently there
Complying with OECD GLP, ISO, US FDA GLP regulatory guidelines, Vanta offers toxicology evaluation services for the pharmaceutical, biotech, food supplements and feed additives industries. The acquisition allows
The deal, funded through a combination of cash, debt and equity, includes the purchase of Omega’s equity for €2.48bn and the assumption of €1.1bn in debt. The acquisition